[
  {
    "ts": null,
    "headline": "2 Dividend Stocks to Buy and Hold For 10 Years",
    "summary": "They are unlikely to resort to dividend cuts anytime soon.",
    "url": "https://finnhub.io/api/news?id=291a9e3a5f54fd6bf1ea32dddcf380ef0d0b10723d8b642f4431bacd9ddf4616",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768850280,
      "headline": "2 Dividend Stocks to Buy and Hold For 10 Years",
      "id": 138180303,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "They are unlikely to resort to dividend cuts anytime soon.",
      "url": "https://finnhub.io/api/news?id=291a9e3a5f54fd6bf1ea32dddcf380ef0d0b10723d8b642f4431bacd9ddf4616"
    }
  },
  {
    "ts": null,
    "headline": "CytomX Stock Rises 31% in a Month: Here's What You Should Know",
    "summary": "CTMX's share jumps 31% in a month after it outlined pipeline progress and 2026 goals led by Varseta-M in advanced colorectal cancer.",
    "url": "https://finnhub.io/api/news?id=c9f2832a6ce58830b0db1e61a3f0309cacc0c0d92b6c5b9e4e66351971909b84",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768832220,
      "headline": "CytomX Stock Rises 31% in a Month: Here's What You Should Know",
      "id": 138177976,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "CTMX's share jumps 31% in a month after it outlined pipeline progress and 2026 goals led by Varseta-M in advanced colorectal cancer.",
      "url": "https://finnhub.io/api/news?id=c9f2832a6ce58830b0db1e61a3f0309cacc0c0d92b6c5b9e4e66351971909b84"
    }
  },
  {
    "ts": null,
    "headline": "What to Expect From Pfizer's Non-Oncology Business in Q4?",
    "summary": "PFE's Q4 outlook centers on Eliquis growth, softer COVID-19 sales and steady demand for key non-oncology drugs ahead of earnings.",
    "url": "https://finnhub.io/api/news?id=9d9a55221c7cabf25da1878a53208465bc3c6639f9dce083cc975a8e8e3eb4a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768831260,
      "headline": "What to Expect From Pfizer's Non-Oncology Business in Q4?",
      "id": 138178028,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PFE's Q4 outlook centers on Eliquis growth, softer COVID-19 sales and steady demand for key non-oncology drugs ahead of earnings.",
      "url": "https://finnhub.io/api/news?id=9d9a55221c7cabf25da1878a53208465bc3c6639f9dce083cc975a8e8e3eb4a8"
    }
  },
  {
    "ts": null,
    "headline": "2 Buffett Stocks to Load Up On—And 1 to Ditch",
    "summary": "With Buffett having officially stepped down at Berkshire Hathaway, investors might continue to follow his lead when it comes to these popular names.",
    "url": "https://finnhub.io/api/news?id=8e462018d0f673ca433438c77cd308003a249dc7073755690fde3b390dc53aa9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768828800,
      "headline": "2 Buffett Stocks to Load Up On—And 1 to Ditch",
      "id": 138186417,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "With Buffett having officially stepped down at Berkshire Hathaway, investors might continue to follow his lead when it comes to these popular names.",
      "url": "https://finnhub.io/api/news?id=8e462018d0f673ca433438c77cd308003a249dc7073755690fde3b390dc53aa9"
    }
  }
]